Faricimab is a monoclonal antibody that was developed by Regeneron Pharmaceuticals and Roche Pharmaceuticals. It is designed to inhibit the action of vascular endothelial growth factor A (VEGF-A), which is a protein that plays an important role in angiogenesis, the formation of new blood vessels. Faricimab is used to treat several eye conditions, including wet age-related macular degeneration and diabetic macular edema. It is administered as an intravitreal injection, which is a procedure that involves injecting the drug directly into the eye. The drug works by blocking the activity of VEGF-A, which stops the growth of abnormal blood vessels in the eye. This helps to reduce swelling and improve vision in patients with these conditions.
Faricimab is a relatively new medication that targets two specific factors involved in age-related macular degeneration (AMD) and diabetic macular edema (DME) [1, 2]. Here's a closer look at this bispecific antibody:
What it Treats:
- Age-related Macular Degeneration (AMD): Faricimab is approved for treating neovascular AMD, a type of AMD characterized by abnormal blood vessel growth in the macula, the central part of the retina responsible for sharp central vision [1].
- Diabetic Macular Edema (DME): DME is a complication of diabetes that causes swelling in the macula due to fluid leakage from blood vessels. Faricimab helps manage DME by reducing this leakage [2].
How it Works:
- Bispecific Antibody: Faricimab is unique because it's a bispecific antibody. This means it can bind to two different targets simultaneously [1]. In this case, Faricimab targets:
- Vascular Endothelial Growth Factor (VEGF-A): VEGF-A is a signaling molecule that promotes blood vessel growth. By binding to VEGF-A, Faricimab helps prevent the abnormal blood vessel growth associated with AMD [1].
- Angiopoietin-2 (Ang-2): Ang-2 is another signaling molecule involved in blood vessel destabilization and leakage. Faricimab binding to Ang-2 helps reduce blood vessel leakage in DME [2].
Benefits:
- Potentially Less Frequent Injections: Faricimab has shown promise in offering extended intervals between injections compared to some other treatments for AMD and DME [1, 2]. This can be beneficial for patients by reducing the number of clinic visits required.
Administration:
- Faricimab is administered via intravitreal injection, meaning it's injected directly into the vitreous cavity of the eye by a healthcare professional [1, 2].
Important Note:
- Faricimab is a prescription medication and should only be used under the supervision of a qualified ophthalmologist (eye doctor) [1, 2].
- It's crucial to discuss the potential benefits and risks of Faricimab treatment with your doctor to determine if it's the right option for you.
This information is intended for educational purposes only and should not be construed as medical advice.